Effects of irradiation using a radioisotope-filled balloon on tissue hyperplasia caused by stent placement in a canine urethral model.
OBJECTIVE
To evaluate 20 Gy and 40 Gy of intraluminal beta-irradiation using a 188Re-7mercaptoacetyltriglycine (MAG3)-filled balloon catheter to reduce tissue hyperplasia caused by covered stent placement for 12 weeks of follow-up in a canine urethral model.


METHODS
Ten dogs underwent 188Re-MAG3-filled balloon dilatation immediately after stent placement; 20 Gy at 1-mm tissue depth in group I (n = 5) and 40 Gy in group II (n = 5), whereas 5 dogs (group III) underwent conventional balloon dilatation only.


RESULTS
There were no significant differences among the three groups for percentage diameter of stenosis, although this was highest in group III. There was a tendency toward lower mean thickness of the epithelial layer and the papillary projection for out-stent area, and thickness of the papillary projection and degree of inflammatory cells for instent area in groups I and II compared with group III. Thickness of the papillary projection in out-stent area was significantly different among the three groups (P = 0.031). It was significantly less thick in group I than in group III (P < 0.05), whereas group II was not significantly different from group III.


CONCLUSIONS
188Re-MAG3-filled balloon dilatation has the potential to reduce tissue hyperplasia after 12 weeks of follow-up in a canine urethral model. The use of 20 Gy compared to 40 Gy did not show significant differences.
Shin
Ji Hoon
JH
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Song
Ho-Young
HY
Moon
Dae Hyuk
DH
Oh
Seung-Jun
SJ
Kim
Jung-Sun
JS
Kim
Eun-Hee
EH
Kim
Tae-Hyung
TH
Woo
Chul-Woong
CW
Kim
Eun-Young
EY
Park
Seong Ho
SH
D000818:Animals; D001918:Brachytherapy / Q000295:instrumentation* / Q000379:methods; D002404:Catheterization / Q000379:methods*; D004195:Disease Models, Animal; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006965:Hyperplasia / Q000209:etiology / Q000532:radiotherapy*; D009842:Oligopeptides / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome; D014521:Urethra / Q000473:pathology / Q000528:radiation effects; D014525:Urethral Stricture / Q000209:etiology / Q000532:radiotherapy*
D009842:Oligopeptides; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C114893:rhenium-mercaptoacetyltriglycine